Oral Chelator Ferriprox Available in U.S. as of December 5
December 5, 2011 – The oral chelator Ferriprox, recently approved by the U.S. Food and Drug Administration, is available to U.S. patients as of today (December 5, 2011).
The drug’s manufacturer, ApoPharma, has set up a system whereby all U.S. patients who have been receiving Ferriprox under a Treatment IND program (also called “compassionate use”) will be contacted about changing over from this program. These patients will continue to receive the drug as previously during the transition period. If you have questions about this transition, please call Ferriprox Total Care at (866) 758-7071; fax is (866) 565-7794. Correspondence can be sent to Ferriprox Total Care Program, 17877 Chesterfield Airport Road, Chesterfield, Missouri 63005. Email is <email@example.com.
ApoPharma is also establishing a Patient Assistance Program to which patients whose insurance does not adequately cover the cost of treatment can apply.
Ferriprox will be distributed in the U.S. via Centric Health Resources, a specialty pharmacy specializing in orphan drugs. Centric will handle the Ferriprox Total Care Program.
A copy of the Ferriprox label can be accessed by clicking here.
CAF will post more information as it becomes available. If you have more questions, please contact Ferriprox Total Care at (866) 758-7071; fax is (866) 565-7794. Correspondence can be sent to Ferriprox Total Care Program, 17877 Chesterfield Airport Road, Chesterfield, Missouri 63005. Email is firstname.lastname@example.org.